WEBULL
News
SPRY
9.70
-3.29%
-0.33
Weekly Report: what happened at SPRY last week (0202-0206)?
Weekly Report · 12h ago
Aptar posts Q4 adjusted net income of USD 82.1 million
Reuters · 3d ago
AptarGroup meldet für das vierte Quartal einen Nettoertrag von 74,3 Mio. USD, ein Anstieg um 19 Prozent
Reuters · 3d ago
What's Going On With Aquestive Therapeutics Stock After FDA Update For Lead Allergic Treatment?
Benzinga · 02/02 18:12
ARS Pharmaceuticals Gets Positive Opinion For Expanded Marketing Authorization For EURneffy By EMA's Committee For Medicinal Products For Human Use
Benzinga · 02/02 13:18
ARS Pharmaceuticals announces CHMP of EMA adopted positive opinion for EURneffy
TipRanks · 02/02 13:11
EU Panel Recommends Approval of ARS Pharma’s EURneffy 1 mg Nasal Adrenaline Spray for Children
Reuters · 02/02 13:01
EURNEFFY® 1 MG (ADRENALINE NASAL SPRAY) RECOMMENDED FOR APPROVAL IN THE EU FOR EMERGENCY TREATMENT OF TYPE 1 ALLERGIC REACTIONS, INCLUDING ANAPHYLAXIS IN CHILDREN WEIGHING ≥15 KG TO <30 KG
Reuters · 02/02 13:00
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 02/02 12:05
Weekly Report: what happened at SPRY last week (0126-0130)?
Weekly Report · 02/02 10:36
EU Regulators Recommend Approval of ALK-Abelló's EURneffy 1 mg Nasal Spray for Pediatric Anaphylaxis
Reuters · 01/29 15:15
Weekly Report: what happened at SPRY last week (0119-0123)?
Weekly Report · 01/26 10:35
ARS Pharmaceuticals announces California eligible for neffyinSchools program
TipRanks · 01/21 13:10
Weekly Report: what happened at SPRY last week (0112-0116)?
Weekly Report · 01/19 10:43
ARS Pharmaceuticals Down Over 13%, on Pace for Largest Percent Decrease Since March -- Data Talk
Dow Jones · 01/12 20:16
Weekly Report: what happened at SPRY last week (0105-0109)?
Weekly Report · 01/12 10:41
SPRY Makes Bullish Cross Above Critical Moving Average
NASDAQ · 01/09 18:50
Bad News For Competitor Turns Into Big Win For ARS Pharma Stock
Benzinga · 01/09 17:32
Aquestive Stock Slides After FDA Flags Issues With Allergy Drug Application
Benzinga · 01/09 16:28
ARS Pharmaceuticals: Buy Rating Reaffirmed on Improved Competitive Outlook After Aquestive’s Anaphylm Setback
TipRanks · 01/09 14:45
More
Webull provides a variety of real-time SPRY stock news. You can receive the latest news about ARS Pharms through multiple platforms. This information may help you make smarter investment decisions.
About SPRY
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.